These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29754725)

  • 21. Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up.
    Corrochano M; Jiménez B; Millón J; Gich I; Rambla M; Gil E; Caparrós P; Macho R; Souto JC
    BMC Cardiovasc Disord; 2020 Apr; 20(1):166. PubMed ID: 32276619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
    Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in a cohort of patients with venous thromboembolism treated with vitamin K antagonists.
    Demelo-Rodríguez P; Postigo-Esteban A; García-Fernández-Bravo I; Agud M; Calpena S; Camacho M; Del Toro-Cervera J
    Thromb Res; 2016 Nov; 147():58-60. PubMed ID: 27676254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).
    Ansell J; Hollowell J; Pengo V; Martinez-Brotons F; Caro J; Drouet L
    J Thromb Thrombolysis; 2007 Apr; 23(2):83-91. PubMed ID: 17221328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital.
    Mark L; Dani G; Vendrey R; Paragh G; Katona A
    Med Sci Monit; 2015 Feb; 21():518-25. PubMed ID: 25686556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study.
    Palareti G; Antonucci E; Lip GY; Testa S; Guazzaloca G; Falanga A; Pengo V; Poli D;
    Thromb Haemost; 2016 Jun; 115(6):1101-8. PubMed ID: 26819229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients.
    Rivera-Caravaca JM; Viedma-Viedma I; Roldán V
    Biol Res Nurs; 2017 Mar; 19(2):198-205. PubMed ID: 27680769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
    Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
    Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study.
    García-Sempere A; Hurtado I; Bejarano-Quisoboni D; Rodríguez-Bernal C; Santa-Ana Y; Peiró S; Sanfélix-Gimeno G
    PLoS One; 2019; 14(2):e0211681. PubMed ID: 30753227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa.
    Mwita JC; Francis JM; Pillay C; Ogah OS; Goshu DY; Agyekum F; Musonda JM; James MC; Tefera E; Kabo T; Ditlhabolo KI; Ndlovu K; Ayodele AY; Mikomangwa WP; Chillo P; Damasceno A; Folson AA; Oyekunle A; Tebuka E; Kalokola F; Forrest K; Dunn H; Karaye K; Jean-Pierre FL; Oljira CF; Assefa T; Taiwo TS; Nwafor CE; Omole O; Anakwue R; Cohen K
    J Thromb Thrombolysis; 2024 Apr; 57(4):613-621. PubMed ID: 38478250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC.
    Elling T; Hak E; Bos JH; Tichelaar VYIG; Veeger NJGM; Meijer K
    Thromb Haemost; 2024 Aug; 124(8):778-790. PubMed ID: 37673103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort.
    Pereira de Sousa L; Burba I; Ruperto C; Lattuada L; Barbone F; Di Chiara A
    J Cardiovasc Med (Hagerstown); 2013 Jul; 14(7):534-40. PubMed ID: 23328227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study.
    van Miert JHA; Veeger NJGM; Ten Cate-Hoek AJ; Piersma-Wichers M; Meijer K
    PLoS One; 2020; 15(7):e0235639. PubMed ID: 32649714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
    ; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
    Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences between patient-driven adherence to vitamin K antagonists and direct oral anticoagulants. Do few missed doses matter? ACO-MEMS Study.
    Solla-Ruiz I; Villanueva-Benito I; Paredes-Galán E; Salterain-González N; Oria-González G; De La Cuesta-Arzamendi F; Querejeta-Iraola R
    Thromb Res; 2019 Jul; 179():20-27. PubMed ID: 31075697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of TTR-INR guided warfarin adjustment protocol to improve time in therapeutic range in patients with atrial fibrillation receiving warfarin.
    Kosum P; Siranart N; Nissaipan K; Laohapiboolrattana W; Sowalertrat W; Triamamornwooth K; Arunphan R; Sriyom A; Rungpradubvong V
    Sci Rep; 2024 May; 14(1):11647. PubMed ID: 38773162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Vicente V; Romiti GF; Romanazzi I; Proietti M; Valdés M; Marín F; Lip GYH
    Int J Cardiol; 2018 Mar; 254():125-131. PubMed ID: 29248163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.